Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma

被引:12
|
作者
Akkok, Cigdem Akalin [2 ]
Hervig, Tor [2 ,3 ]
Stamnesfet, Siren [2 ]
Nesthus, Ingerid
Melve, Guro K. [2 ]
Lassalle, Philippe [4 ]
Bruserud, Oystein [1 ,5 ]
机构
[1] Univ Bergen, Sect Hematol, Inst Internal Med, Haukeland Univ Hosp,Dept Med, N-5021 Bergen, Norway
[2] Haukeland Hosp, Dept Immunol & Transfus Med, N-5021 Bergen, Norway
[3] Univ Bergen, Gades Inst, N-5021 Bergen, Norway
[4] Inst Pasteur, INSERM Unit 416, F-59019 Lille, France
[5] Univ Bergen, Inst Internal Med, Sect Hematol, N-5021 Bergen, Norway
关键词
angiogenesis; cytokines; hepatocyte growth factor; stem cell harvesting; HEPATOCYTE GROWTH-FACTOR; ACUTE MYELOGENOUS LEUKEMIA; TUMOR DORMANCY; CANCER; ANGIOGENESIS; RISK; TRANSPLANTATION; CHEMOTHERAPY; MOBILIZATION; MOLECULE-1;
D O I
10.3109/14653249.2011.605117
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background aims. Pro-angiogenic cytokines can affect myeloma cell proliferation directly and indirectly through stimulation of cancer-associated angiogenesis. Methods. We investigated how peripheral blood stem cell (PBSC) collection affected plasma angioregulatory cytokine levels in 15 consecutive myeloma patients. Results. Plasma levels of hepatocyte growth factor (HGF) were significantly increased prior to apheresis in patients compared with donors, and a further increase was detected immediately after PBSC apheresis. HGF levels decreased within 24 h, but were still higher than the levels in healthy donors, whose HGF levels were not altered by platelet apheresis. Pre-apheresis levels of other angioregulatory cytokines, angiopoietin-2 and vascular endothelial growth factor (VEGF), were also increased in patients, whereas angiopoietin-1, angiogenin and basic fibroblast growth factor levels did not differ from healthy controls. PBSC harvesting decreased angiopoietin-1 and VEGF levels, increased the microvascular endothelial cell marker endocan levels but did not affect the other mediators. Conclusions. Our results show that PBSC apheresis alters systemic angioregulatory profiles in myeloma patients. This cytokine modulation is not a general characteristic of all apheresis procedures and was not seen in healthy platelet donors.
引用
收藏
页码:1259 / 1268
页数:10
相关论文
共 50 条
  • [31] No influence of previous thalidomide administration on peripheral blood stem cell collection in patients with multiple myeloma.
    Breitkreutz, I
    Benner, A
    Cremer, FW
    Herrmann, D
    Ho, AD
    Goldschmidt, H
    BLOOD, 2004, 104 (11) : 307B - 307B
  • [32] Peripheral blood stem cell transplantation (PBSCT) in the outpatient setting: Feasibility in multiple myeloma patients.
    Morabito, F
    Martino, M
    Callea, V
    Messina, G
    Console, G
    Irrera, G
    Stelitano, C
    Pucci, G
    Jaksic, B
    Brugiatelli, M
    Iacopino, P
    BLOOD, 2000, 96 (11) : 373B - 373B
  • [33] A longitudinal study of molecular responses in patients undergoing peripheral blood stem cell transplantation for multiple myeloma
    Ahsan, G
    Schey, SA
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 483 - 483
  • [34] Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma
    Sahin, Ugur
    Demirer, Taner
    JOURNAL OF CLINICAL APHERESIS, 2018, 33 (03) : 357 - 370
  • [35] Hemostatic Disorders and Thrombotic Events in Multiple Myeloma Patients during Peripheral Blood Stem Cell Mobilization
    Urnova, Evdokia S.
    Mendeleeva, Larisa P.
    Pokrovskaya, Olga S.
    Gracheva, Marina A.
    Gemdzhian, Eduard G.
    Tarandovsky, Ivan D.
    Firsova, Maiia V.
    Nareiko, Mariya V.
    Vasil'ev, Sergei A.
    Savchenko, Valeri G.
    BLOOD, 2014, 124 (21)
  • [36] Predictive factors in peripheral blood stem cell (PBSC) harvest in multiple myeloma (MM) patients.
    Worel, N
    Schlogl, E
    Rabitsch, W
    Kuhrer, I
    Greinix, H
    Hocker, P
    BLOOD, 1997, 90 (10) : 4272 - 4272
  • [37] Transplantation in patients with multiple myeloma: A multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant
    Varterasian, M
    Janakiraman, N
    Karanes, C
    Abella, E
    Uberti, J
    Dragovic, J
    Raman, SBK
    AlKatib, A
    Du, W
    Silver, SM
    Adams, PT
    Sensenbrenner, L
    Ratanatharathorn, V
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (05): : 462 - 466
  • [38] Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma
    Burzynski, Julianna Aleathea
    Toro, Juan J.
    Patel, Rakhi Chhaganbhai
    Lee, Shuko
    Greene, Rebecca Elizabeth
    Ochoa-Bayona, Jose Leonel
    Frei, Christopher Raymond
    Freytes, Cesar O.
    LEUKEMIA & LYMPHOMA, 2009, 50 (09) : 1442 - 1447
  • [39] Increased Risk of Citrate Reactions in Patients with Multiple Myeloma During Peripheral Blood Stem Cell Leukapheresis
    Adamski, Jill
    Griffin, Adrienne Carruth
    Eisenmann, Christa
    Milone, Michael C.
    Sachais, Bruce S.
    JOURNAL OF CLINICAL APHERESIS, 2010, 25 (04) : 188 - 194
  • [40] Predictive factors for poor peripheral blood stem cell mobilization in patients with malignant lymphoma and multiple myeloma
    Kim, Da Jung
    Jung, Sung Mi
    Jeong, Jee-Yeong
    Lee, Ji Hyun
    Cho, Su-Hee
    Jung, Ki Sun
    Jo, Jae-Cheol
    Park, Silvia
    Lee, Ho Sup
    BONE MARROW TRANSPLANTATION, 2018, 53 : 783 - 783